Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHST NASDAQ:GNLX NASDAQ:ITRM NASDAQ:MCRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$7.67-0.3%$7.03$4.66▼$7.99$126.28M0.679,400 shs717 shsGNLXGenelux$3.51$3.03$1.60▼$5.89$132.54M-0.32159,325 shs139,024 shsITRMIterum Therapeutics$0.71-2.5%$0.94$0.68▼$3.02$30.84M2.85847,059 shs3.25 million shsMCRBSeres Therapeutics$14.78+5.6%$10.47$6.53▼$26.40$122.17M2.9149,374 shs83,419 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences-0.26%+2.27%+11.16%+17.10%+766,999,900.00%GNLXGenelux0.00%+3.54%+17.79%+50.64%+102.89%ITRMIterum Therapeutics-2.49%-8.49%-24.94%-28.38%-40.52%MCRBSeres Therapeutics+5.65%+11.63%+30.16%+72.87%-40.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/AGNLXGenelux1.1517 of 5 stars3.61.00.00.01.10.00.0ITRMIterum Therapeutics1.5943 of 5 stars3.53.00.00.01.40.00.0MCRBSeres Therapeutics2.9559 of 5 stars2.91.00.04.61.70.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 3.00Buy$13.6778.18% UpsideGNLXGenelux 3.20Buy$17.75405.70% UpsideITRMIterum Therapeutics 3.00Buy$9.001,160.86% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67398.42% UpsideCurrent Analyst Ratings BreakdownLatest ITRM, MCRB, GNLX, and BHST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.005/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.005/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.005/5/2025BHSTBioHarvest SciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$27.70M4.55N/AN/A$0.08 per share95.88GNLXGeneluxN/AN/AN/AN/A$0.76 per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/AMCRBSeres Therapeutics$126.32M1.02N/AN/A$1.61 per share9.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$12.91M-$0.50N/AN/AN/A-31.30%-307.04%-33.21%8/11/2025 (Confirmed)GNLXGenelux-$29.87M-$0.88N/AN/AN/AN/A-93.04%-74.17%8/13/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/5/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/6/2025 (Estimated)Latest ITRM, MCRB, GNLX, and BHST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/AGNLXGenelux-$0.22N/AN/AN/AN/AN/A8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72N/AN/AN/AN/AN/A8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13N/AN/AN/AN/AN/A5/15/2025Q1 2025BHSTBioHarvest Sciences-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/A5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest SciencesN/A0.510.30GNLXGeneluxN/A4.674.67ITRMIterum TherapeuticsN/A3.723.58MCRBSeres TherapeuticsN/A2.112.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/AGNLXGenelux37.33%ITRMIterum Therapeutics9.21%MCRBSeres Therapeutics59.34%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/AGNLXGenelux9.30%ITRMIterum Therapeutics2.40%MCRBSeres Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A16.43 millionN/AN/AGNLXGenelux1037.76 million34.44 millionNot OptionableITRMIterum Therapeutics1042.13 million41.12 millionNot OptionableMCRBSeres Therapeutics3308.73 million8.32 millionOptionableITRM, MCRB, GNLX, and BHST HeadlinesRecent News About These CompaniesSeres Therapeutics (MCRB) Expected to Announce Earnings on WednesdayJuly 31, 2025 | marketbeat.comSeres Therapeutics: Speculative Gem Backed By SER‑155 FDA BreakthroughJuly 31, 2025 | seekingalpha.comSeres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025July 22, 2025 | globenewswire.comSBI Securities Co. Ltd. Purchases 48,013 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB)July 20, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Cross Above Fifty Day Moving Average - What's Next?July 5, 2025 | marketbeat.comSeres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual MeetingMay 27, 2025 | globenewswire.comSeres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?May 23, 2025 | zacks.comWall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to TradeMay 16, 2025 | zacks.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call TranscriptMay 9, 2025 | insidermonkey.comChardan Capital Downgrades Seres Therapeutics (MCRB)May 9, 2025 | msn.comSeres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comSeres Therapeutics reports Q1 EPS $3.75, consensus $1.97May 7, 2025 | msn.comSeres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7, 2025 | globenewswire.comSeres Therapeutics Q1 2025 Earnings PreviewMay 6, 2025 | msn.comWhy Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 5.09%May 6, 2025 | aaii.comASeres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune DiseasesApril 29, 2025 | globenewswire.comPetri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock splitApril 24, 2025 | bizjournals.comSeres Therapeutics trading resumesApril 24, 2025 | markets.businessinsider.comSeres Therapeutics trading halted, volatility trading pauseApril 24, 2025 | markets.businessinsider.comSeres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025April 23, 2025 | globenewswire.comSeres Therapeutics trading halted, news pendingApril 22, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeITRM, MCRB, GNLX, and BHST Company DescriptionsBioHarvest Sciences NASDAQ:BHST$7.67 -0.02 (-0.26%) As of 08/4/2025 03:41 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Genelux NASDAQ:GNLX$3.51 0.00 (0.00%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$3.52 +0.01 (+0.14%) As of 08/4/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Iterum Therapeutics NASDAQ:ITRM$0.71 -0.02 (-2.49%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$0.73 +0.02 (+2.27%) As of 08/4/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Seres Therapeutics NASDAQ:MCRB$14.78 +0.79 (+5.65%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$14.58 -0.21 (-1.39%) As of 08/4/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How 2 Deals in 48 Hours Changed Everything for Joby Aviation Here's Why Traders Turned Bullish on Boeing Stock Onsemi’s August Pullback Is a Signal to Buy for Tech Investors Strategy Insiders Buy In While Analysts Predict Big Upside Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging Yes, You Can Get Dividends in Tech: 3 Stocks With Yield + Upside MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
